|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 依帕列净能够减缓2型糖尿病的肾脏病进展显示文摘2型糖尿病是大血管和微血管疾病主要的危险因素。大约35%的2型糖尿病患者会发生肾脏病,导致死亡率升高。强化降糖策略已被证明能够在2型糖尿病患者中减少肾脏并发症的替代标记物,但其改善晚期肾脏并发症的证据迄今十分有限。尽管使用了优化血糖控制和单药阻断肾素-血管紧张素-醛固酮系统(RAAS),2型糖尿病患者的死亡风险和心肾并发症仍然在增加。 | 王建中 Wanner C Inzucchi SE Lachin JM | 2016 | 中华肾病研究电子杂志2016，5，4： | 6 |
| 2 | Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial-Revisited 显示文摘 | Lachin JM Genuths NathanDM | 2008 | Diabetes2008，57，： | 1 |
| 3 | Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus显示文摘 | Nathan DM Lachin J Cleary P | 2003 | N Engl J Med2003，348，23： | 1 |
| 4 | Fluoroenzymometric method to measure cardiac troponin I in sera of patients with myocardial infarction显示文摘 | Zaninotto M Altinier S Lachin M | 1996 | Clin Chem1996，42，9： | 1 |
| 5 | Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study显示文摘 | Lachin JM Orchard TJ Nathan DM | 2014 | Diabetes Care2014，37，： | 1 |
| 6 | Rosiglitazone-associated fractures in type 2 diabetes:an analysis from A Diabetes Out- come Progression Trial(ADOPT) 显示文摘 | Kahn SE Zinman B Lachin JM | 2008 | Diabetes Care2008，31，5： | 1 |
| 7 | Empagliflozin,cardiovascular outcomes, and mortality in type 2 diabetes显示文摘 | Zinman B Wanner C Lachin JM | 2015 | N Engl J Med2015，373，22： | 1 |
| 8 | Intensive diabetes therapy andcarotid intima-media thickness in type I diabetes mellitus显示文摘 | Nathan DM Lachin J Cleary P | 2003 | N Engl JMed2003，348，23： | 1 |
| 9 | Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes显示文摘 | Zinman B Wanner C Lachin JM | 2015 | N Engl J Med2015，373，22： | 1 |
| 10 | Troponin T,creatinekinase MB mass,and creatine kinase MB isoform ratio in the detection of myocardial damage during non-surgical coronary revascularization显示文摘 | Reimers B Lachin M Cacciavillani L | 1997 | Int J Cardiol1997，60，1： | 1 |
| 11 | Rationale, design, and baseline characteristics of a randomized, placebo controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME) 显示文摘 | Zinman B Inzucchi SE Lachin JM | 2014 | Cardiovasc Diabetol2014，13，： | 1 |
| 12 | Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited显示文摘 | Lachin JM Genuth S Nathan DM | 2008 | Diabetes2008，57，4： | 1 |
| 13 | Rosiglitazone-associated fractures in type 2 diabetes:an Analysis from A Diabetes Outcome Progression Trial (ADOPT)显示文摘 | Kahn SE Zinman B Lachin JM | | Diabetes Care0，，： | 1 |
| 14 | Rosiglitazone- associated fractures in type 2 diabetes : an analysis from a diabetes outcome progression trial (ADOPT) 显示文摘 | Kahn SE Zinman B Lachin JM | 2008 | Diabetes Care2008，31，5： | 1 |
| 15 | Link-based Models for Survival Data with Interval and Continuous Time Censoring显示文摘 | YOUNES N LACHIN J | 1997 | Biometrics1997，53，4： | 1 |
| 16 | Effect of glyce- mic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited 显示文摘 | Lachin JM Genuth S Nathan DM | 2008 | Diabetes2008，57，4： | 1 |
| 17 | Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes显示文摘 | Zinman B Wanner C Lachin JM | 2015 | N Engl J Med2015，373，22： | 1 |
| 18 | Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus显示文摘 | NATHAN DM LACHIN J CLEARY P | 2003 | N Engl J Med2003，348，： | 1 |
| 19 | Rosiglitazone-associated fractures in type w diabetes:an Analysis from A Diabetes Outcome Progression Trial(ADOPT)显示文摘 | Kahn SE Zinman B Lachin JM | 2008 | Diabetes Care2008，31，5： | 1 |
| 20 | Empagliflozin, Cardiovascular Outcomes,and Mortality in Type 2 Diabetes显示文摘 | Zinman B Wanner C Lachin JM | 2015 | N Engl J Med2015，373，22： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员